Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-8.49 Insider Own0.30% Shs Outstand392.44M Perf Week-0.53%
Market Cap120.68B Forward P/E14.33 EPS next Y21.46 Insider Trans- Shs Float391.02M Perf Month0.36%
Income-2262.20M PEG- EPS next Q4.40 Inst Own90.80% Short Float1.26% Perf Quarter3.06%
Sales14.64B P/S8.24 EPS this Y-40.80% Inst Trans38.84% Short Ratio2.15 Perf Half Y19.46%
Book/sh229.62 P/B1.34 EPS next Y20.21% ROA-3.20% Target Price348.90 Perf Year38.71%
Cash/sh5.43 P/C56.63 EPS next 5Y17.25% ROE-6.50% 52W Range201.91 - 317.72 Perf YTD19.46%
Dividend0.20 P/FCF61.85 EPS past 5Y-42.20% ROI-2.70% 52W High-3.21% Beta0.27
Dividend %0.07% Quick Ratio1.00 Sales past 5Y36.10% Gross Margin54.10% 52W Low52.30% ATR5.57
Employees21600 Current Ratio1.40 Sales Q/Q59.50% Oper. Margin-10.80% RSI (14)56.78 Volatility2.04% 1.72%
OptionableYes Debt/Eq0.67 EPS Q/Q-436.40% Profit Margin-14.80% Rel Volume0.48 Prev Close306.91
ShortableNo LT Debt/Eq0.64 EarningsAug 05 BMO Payout- Avg Volume2.28M Price307.51
Recom1.70 SMA201.49% SMA502.83% SMA20011.54% Volume1,084,483 Change0.20%
Jul-02-15 09:46AM  Investors Wade Into 'Wide Moats' for Long-Term Gains
07:47AM  How much will you spend this July 4th?
Jul-01-15 01:13PM  Top Takeaways From BMO's Specialty Pharma Day
12:43PM  Allergan and Valeant: Who'll See the Bigger Benefit from Irritable Bowels? at
02:38AM  Willis-Towers Watson: A Merger of Equals---Not Exactly at The Wall Street Journal
12:39AM  Willis-Towers Watson: A Merger of EqualsNot Exactly at The Wall Street Journal
Jun-30-15 11:48AM  A New Rider in the Perrigo, Mylan, Teva Merger Merry-Go-Round at
Jun-29-15 04:05PM  Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast PR Newswire
10:48AM  Billionaires Cooperman and Larry Robbins Are Piling Into These Stocks at Insider Monkey
10:17AM  Billionaire Halvorsen and John Lykouretzos Are Betting On The Same Stocks at Insider Monkey
07:00AM  5 Rocket Stocks to Sidestep the Greek Drama at TheStreet
Jun-26-15 04:45PM  Eli Lilly Wins Alimta Patent Lawsuit in the UK, Shares Up - Analyst Blog
04:45PM  Zoetis Loses All Of Thursday's Spike On Valeant Buzz at Investor's Business Daily
03:38PM  Horizon Pharma Seen In Deal-Making Mode at Investor's Business Daily
01:46PM  20 Biotech and Healthcare Stocks The Richest Hedge Fund Billionaires Are Buying And Selling Now at Forbes
11:54AM  Valeant, Zoetis Shares in the Dog House on Takeout Speculation at
11:51AM  John Paulson riding health-care wave with new fund at CNBC
09:53AM  Cramer's Stop Trading: Intel & Horizon Pharma
09:22AM  Cramer's Mad Dash: Finish Line's victory lap
07:38AM  Valeant Pharmaceuticals And Zoetis: A True Mega Deal Is On The Horizon at Forbes
Jun-25-15 09:36AM  Third Point and Senator Investment Are Investing In The Same Stocks at Insider Monkey
08:37AM  Eli Lilly Wins Alimta Patent Case in U.K. at The Wall Street Journal
Jun-24-15 05:50PM  IBD Market Wrap - 06/24/15
10:14AM  How much the best-performing and worst-performing CEOs got paid at MarketWatch
09:39AM  Bill Ackman and Scott Ferguson Are Investing In The Same Stocks at Insider Monkey
Jun-23-15 06:39PM  Julian Robertson Adds 16 New Stakes to Portfolio
06:13PM  Cramer: Stocks killing it in a negative market at CNBC
03:57PM  FOMC and Greece Negotiation Breakdown Impact Financial Markets
Jun-22-15 06:00PM  Cramer: Top 7 plays on Greece
12:51PM  Jim Cramer: Netflix Can Go Higher but Don't Expect It to Double at TheStreet
09:40AM  Billionaire Mandels Investing Acumen Has Led Him To Williams Companies Inc and These Two Stocks at Insider Monkey
Jun-21-15 10:23AM  Allergan aims to keep beauty lead as needle replaces the knife at Financial Times
Jun-19-15 06:00AM  Jim Cramer's Top Takeaways: BioMarin, Radius Health, Allergan, Diageo, Wayfair at TheStreet
Jun-18-15 06:18PM  Cramer: Secret pattern to unlocking biotech riches at CNBC
04:45PM  KYTHERA Soars on $2.1 Billion Buyout Offer from Allergan - Analyst Blog
10:10AM  Company News for June 18, 2015 - Corporate Summary
10:09AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of KYTHERA Biopharmaceuticals, Inc. of Commencement of an Investigation Concerning the Fairness of the Sale of the Company to Allergan plc -- KYTH PR Newswire
06:00AM  Jim Cramer's Top Takeaways: Palo Alto Networks, Tesla, Ambarella, Allergan, Wingstop, Alkermes at TheStreet
01:14AM  Edited Transcript of AGN M&A conference call or presentation 17-Jun-15 12:30pm GMT
Apr-01-15 12:35PM  Valeant closes $11B deal for Raleigh's Salix Pharmaceuticals at
Mar-24-15 02:35PM  Salix had a $13B offer on the table before accounting problems crashed share price at
Mar-18-15 08:11AM  ALLERGAN INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure t
Mar-17-15 09:49PM  Sale of Allergan to Actavis is finalized; CEO David Pyott stepping down at Los Angeles Times
06:49PM  Actavis' Depression Drug Gains FDA Approval for New Dose - Analyst Blog
06:00PM  Cramer: Market cross currents
05:44PM  Valeant (VRX) Raises Salix Offer, Endo Withdraws Proposal - Analyst Blog
03:45PM  Allergan sale complete, CEO Pyott steps down at
01:40PM  American Airlines Group (AAL) to Enter Coveted S&P 500 - Analyst Blog
01:39PM  Allergan sale to Actavis complete; CEO David Pyott is leaving at Los Angeles Times
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands. The North American Generics and International segment develops, manufactures, and sells generic, branded generic, and OTC pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies, pharmacy chains and buying groups, and physician's offices. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, gastroenterology, urology, and dermatology areas. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers. It has a collaboration agreements with Amgen, Inc. to develop and commercialize biosimilar versions of Herceptin, Avastin, Rituxan/Mab Thera, and Erbitux; Ironwood Pharmaceuticals to develop and commercialize Linzessfor the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; Sanofi-Aventis U.S. LLC; and Trevena for the development of TRV027. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Parsippany, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PYOTT DAVID E IChairman of the Board and CEOFeb 20Option Exercise0.001,3790166,379Feb 24 09:52 PM
Gangolli Julian SCVP & Pres, North AmericaFeb 20Option Exercise0.0051402,418Feb 24 09:44 PM